TY  - JOUR 
AU  - Antón Aparicio, Luis Miguel
PY  - 2014
SN  - 1078-0432
UR  - http://hdl.handle.net/20.500.11940/8460
LA  - eng
TI  - Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer
DO  - 10.1158/1078-0432.ccr-13-1869
T2  - CLINICAL CANCER RESEARCH
M2  - 1925
VL  - 20
ER  -